ALLIFE MEDICINE INC. was co-founded in 2017 by Professor Gu Yuchun, together with scientists from China and the UK. It is a technology-driven enterprise with the mission of "making innovative medicines accessible and affordable", dedicated to curing diseases, saving lives, and extending life expectancy through regenerative medicine approaches.
At the core of the company's platform is its self-developed iPSC reprogramming technology, which forms the basis of a globally leading iPSC platform. The company's core R&D team comes from internationally renowned institutions such as Peking University, the University of Cambridge, Aston University, and the Wellcome Sanger Institute. The company has over 150 R&D personnel, including more than 40 PhD holders, of whom nine are postdoctoral researchers. Employees with PhD or Master's degrees account for over 70 percent, while those with a Bachelor's degree or above represent more than 95 percent.
Building upon its proprietary, globally competitive iPSC technology platform, Allife Medicine actively conducts R&D and translation of downstream cell-based drugs. The company has developed various products, including vascular Endothelial Progenitor Cells (EPCs), islet cells, retinal pigment epithelial cells, red blood cells, platelets, and various engineered immune cells. This has established a complete system within the iPSC field, spanning from basic research to industrialization, marking China's first successful IND submission for iPSC-derived therapeutics.
The enterprise holds two China-firsts and several world-firsts:
1. ALF201, the world's first iPSC-derived EPC injection for treating acute ischemic stroke, received IND approval on April 26, 2022. This product is also the first in China to receive IND approval for an iPSC technology-derived drug. ALF201 has completed Phase I clinical trials and has been approved to proceed to Phase II. Phase I results showed promising therapeutic effects in moderate to severe stroke patients.
2. ALF101, a CAR-NK injection targeting ovarian cancer, received IND approval on November 11, 2021, marking the first CAR-NK drug in China to obtain IND approval. Its Phase I clinical trial is currently ongoing.
3. Additionally, ALF202, the world's first iPSC-derived EPC injection for treating critical limb ischemia, received IND approval on November 15, 2023, and has completed dosing for all patients in its Phase I trial.
Based on its iPSC reprogramming technology, the company has developed projects such as clinical-grade iPSC cell banks and an iPSC hematopoietic factory, which hold leading positions and competitive advantages both domestically and internationally. The company has also completed Pre-IND applications for several Class I New Drugs, including islet cells (for diabetes) and RPE cells (for macular degeneration), achieving a diversified pipeline layout. In the next three years, the company aims to secure marketing approval for its first iPSC-derived drug.
The company has established a comprehensive intellectual property (IP) portfolio, having filed over 200 related IP applications, including more than 120 invention patents, with over 70 patents granted. It also holds over 30 international PCT patent applications, building a solid IP barrier. Allife Medicine has been honored with numerous domestic and international awards, including being recognized as a Beijing High-Tech Enterprise, Zhongguancun High-Tech Enterprise, Beijing Municipal Enterprise Technology R&D Institution, Beijing Technology-based SME, Beijing Postdoctoral Workstation, Beijing Economic-Technological Development Area's "Pioneering Enterprise Filling a Void", 2024 Beijing Intellectual Property Advantageous Unit, and Beijing Specialized, Sophisticated, Distinctive, and Innovative SME. Furthermore, Allife Medicine has received accolades such as the 2022 Top 100 Innovative Breakthrough Enterprises, 2022 Shanghai iMED CGT Field Leader Enterprise, Most Innovative Chinese Biopharmaceutical Enterprise Award, UK GHP's 2023 & 2024 Asia's Best Cell Biology Company, 2023 Most Investable Biotech Rising Star, Frost & Sullivan's "First Mover in iPSC-derived EPC-based Cell Drug Development Platform", US Life Science Review's 2024 Best Stem Cell Company, GHP's 2025 Asia-Pacific Best iPSC & Cell Therapy Innovation Enterprise, and KPMG China Bio-Science Innovation Leader Top 50.
Leveraging its robust R&D capabilities to drive industry development, the company engages in technology licensing, technical services, and cell derivative development for downstream enterprises. It is establishing a domestic CDMO production line for universal cell therapies to achieve large-scale manufacturing of universal cell drugs. Simultaneously, it is implementing medical technology application and achievement transformation through pilot zones like Bo'ao Lecheng, Beidaihe, and Guangzhou Nansha. This completes the seamless connection from scientific research to public benefit, ensuring rapid translation of technological innovation into real-world applications and creating social value.